SCHEDULE: Panacea Funds Adjust Atara Biotherapeutics Stake

Panacea Venture entities, including James Huang, have updated their beneficial ownership in Atara Biotherapeutics, Inc., reporting a sale of shares and warrant exercises.

Summary

• Panacea Innovation Limited and James Huang collectively beneficially own 1,632,345 shares, representing 19.99% of Atara Biotherapeutics, Inc. common stock.
• This includes 259,163 immediately exercisable warrants, with an exercise limitation to prevent exceeding 19.99% ownership.
• Panacea Opportunity Fund I, L.P. exercised warrants to acquire 48,736 shares on November 28, 2025.
• Panacea Venture Healthcare Fund II, L.P. sold 80,554 shares in open market transactions on January 12, 2026, at a weighted average price of $6.0707 per share.
• The total outstanding shares of Common Stock for Atara Biotherapeutics, Inc. were 7,258,971 as of November 28, 2025.

Sentiment

Score: 4

Explanation: The sale of a notable number of shares by a significant investor, even while maintaining a substantial stake, generally indicates a slight negative sentiment or a strategic re-evaluation, which could be perceived as a lack of stronger conviction in the immediate future of the company.

Positives

• Warrants held by Panacea Opportunity Fund I, L.P. were exercised, converting potential dilution into actual shares.

Negatives

• Panacea Venture Healthcare Fund II, L.P. sold 80,554 shares, indicating a reduction in their stake.

Risks

• A significant shareholder reducing their stake could signal a lack of confidence or a shift in investment strategy, potentially impacting investor sentiment.
• The 19.99% ownership cap on warrant exercise limits the immediate upside for the reporting persons from their warrants.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the issuer or reporting persons regarding future business operations or financial performance, beyond the inherent nature of investment decisions.

Industry Context

This filing reflects an investment fund's adjustment to its stake in a biotechnology company. Such adjustments are common in the biotech sector, where investment strategies can shift based on clinical trial progress, regulatory milestones, or broader market conditions. The sale of shares by a significant investor could be interpreted by the market as a re-evaluation of the company's near-term prospects or a portfolio rebalancing.

Stakeholder Impact

• Shareholders: The sale by a significant investor could lead to negative market sentiment and potentially impact share price.
• Company Management: May need to address investor concerns regarding the reduction in stake by a major holder.

Next Steps

• The reporting persons undertake to provide full information regarding the number of shares sold at each separate price for the January 12, 2026 transaction upon request.

Key Dates

Recommendation

While a significant investor has reduced their stake, they still maintain a substantial beneficial ownership of 19.99%. The sale of 80,554 shares at $6.0707 per share represents a partial divestment rather than a full exit. The exercise of warrants by another Panacea fund also shows continued engagement. Investors should monitor future filings and company performance for clearer directional signals, but the current action suggests a rebalancing rather than a complete loss of confidence, warranting a 'hold' position.

Keywords

Atara Biotherapeutics, Panacea Venture, James Huang, Schedule 13D, Beneficial Ownership, Stock Sale, Warrant Exercise, Biotechnology, Investment Fund